CDMO Landscape Seeing Changes as Consolidation Continues

The expected growth of the global bio/pharmaceutical market is pushing for the continued evolution of the CDMO arena.

Consolidation in the contract manufacturing landscape in recent years has resulted in service providers that now have varied scientific, technical, and technology expertise. The ability to provide real-time data analytics is in high demand, and there is a need for innovative flow filtration technologies, factors that seem to be driving some of this consolidation.

Read this article in BioPharm International’s Partnerships for Outsourcing May 2021 eBook.

About the author

Feliza Mirasol is the science editor for BioPharm International.

Article Details

BioPharm International
eBook: Partnerships for Outsourcing, May 2021
May 2021
Pages: 4–6

Citations

When referring to this article, please cite it as F. Mirasol, “CDMO Landscape Seeing Changes as Consolidation Continues," BioPharm International Partnerships for Outsourcing eBook (May 2021).

Articles in this issue

over 4 years ago

Article

RNA’s Expanding Horizons

over 4 years ago

Article

Challenges When Outsourcing Viral Safety Services

over 4 years ago

Article

Ensuring Contract Manufacturing Facilities Are Up to Speed

over 4 years ago

Article

Succeeding with Remote Audits

over 4 years ago

Article

Demystifying Complex Clinical Trial Kit Prep

over 4 years ago

Article

CDMO Partnerships Boost Company Capabilities

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!